+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

S

Actively Recruiting

This trial studies adults aged 50 to under 80 with mild or moderate calcific aortic valve stenosis and elevated lipoproteina levels. Researchers are assessing the safety, tolerability, and ability of pelacarsen TQJ230 given once monthly by injection to slow the progression of this heart valve condition. The study compares pelacarsen to a placebo in a randomized, double-blind design. Participants receive either pelacarsen 80 mg or a matching placebo as a subcutaneous injection monthly. They continue treatment and monitoring for up to 36 months to observe changes in heart valve narrowing and calcium buildup. The study also tracks lipoproteina levels and clinical heart-related events during this period. Throughout the study, participants will have regular assessments including imaging to measure aortic valve function and calcium score, blood tests for lipoproteina, and monitoring for safety. The main outcomes analyzed after 36 months include changes in valve jet velocity and calcium score, alongside clinical events. Participants remain under medical care while being observed for any effects of the study drug or placebo.

Age: 50Years - 80YearsAll GendersPhase 2
140 locations
G

Actively Recruiting

Researchers are studying the impact and burden of three skin conditions moderate or severe alopecia areata, non-segmental vitiligo, and moderate to severe hidradenitis suppurativa. The study includes adolescents and adults and aims to understand how these conditions affect quality of life and daily functioning in a large global population. This is an observational study where participants with each condition will have a single visit for data collection following routine clinical practice. No experimental treatments are given instead, the study gathers information during this one visit to assess disease characteristics and impact. During the visit, participants will complete questionnaires and clinical assessments specific to their condition. These include tools measuring symptom impact, hair loss severity, skin depigmentation, and quality of life related to each disease. This helps researchers better understand the real-world burden of these conditions. Participation involves only this one visit, with no long-term follow-up or additional procedures.

Age: 12Years +All Genders
116 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
C

Actively Recruiting

Researchers are evaluating the performance and safety of Artelac Complete MDO eye drops compared to VISMED MULTI eye drops in managing moderate to severe dry eye disease. This study is a double-masked, randomized, parallel group trial aiming to assess whether Artelac is not inferior to VISMED MULTI in treating this condition, focusing on patients with dry eye secondary to specific disorders. Participants self-administer either Artelac Complete MDO or VISMED MULTI eye drops. Prior to randomization, they will use a preservative-free tear substitute for at least 10 days. The study includes a screening period followed by treatment and assessments over approximately 90 days. The primary outcome measure is the change in total OSDI score from baseline to Day 90. Participants will undergo screening to confirm eligibility, including history review and clinical assessments of dry eye severity. During the study, they will be monitored for symptoms and signs of dry eye, with visits at baseline and Day 90 to measure treatment effects. Safety and adherence are tracked throughout, with the total study duration lasting about three months.

Age: 18Years +All GendersPhase Not Applicable
12 locations
S

Actively Recruiting

Researchers are investigating the real-world use of encorafenib plus binimetinib for patients with unresectable advanced or metastatic melanoma that has a BRAF V600 mutation. This observational study focuses on documenting treatment effects, quality of life, safety, and tolerability after these drugs became commercially available in Germany, Austria, and Switzerland. The study specifically looks at patients treated in the first and second line settings after prior checkpoint inhibitor therapy. The study observes patients who are treated with encorafenib plus binimetinib according to the approved product guidelines. Participants may have started this treatment up to six months before joining the study or may begin treatment soon after enrollment. The study tracks treatment details, effectiveness, side effects, and patient-reported outcomes over a median treatment duration of about 12 months, with a total observation period of up to 90 months. Participants will be followed through regular documentation of their disease and treatment progress, including patient and disease profiles, treatment sequences, adverse events, and quality of life assessments using questionnaires. The main outcome measured is progression-free survival at 12 months after treatment start. Researchers will also evaluate treatment duration, interruptions, dose intensity, and physician satisfaction. Long-term safety and prognostic factors will be monitored throughout the observation period until study completion in September 2027.

Age: 18Years +All Genders
59 locations
C

Actively Recruiting

This research aims to compare the vision outcomes and patient satisfaction of six different types of artificial lenses intraocular lenses or IOLs implanted during cataract surgery. It focuses on how well these lenses help people see at far, middle, and near distances, how satisfied patients are with their vision after surgery, and how often glasses are still needed. The study addresses an important need for better intermediate vision following cataract surgery by evaluating modern extended depth-of-focus lenses against a standard monofocal lens. Participants will have cataract surgery in both eyes, 1 to 2 weeks apart, receiving one of six lens types TECNIS Eyhance, AcrySof IQ Vivity, LuxSmart, Rayner EMV, Eyecryl SERT, or the standard monofocal CT ASPHINA 409M lens. The procedure is standardized with a single experienced surgeon performing all implantations. Each lens uses a different optical design to potentially improve vision at various distances, especially intermediate vision important for daily tasks. During the study, participants undergo vision tests at multiple distances, contrast sensitivity tests under different lighting conditions, and fill out questionnaires about their vision quality and daily activities. Follow-up visits occur at 1 day, 1 week, 1 month, and 3 months after surgery to monitor visual performance, patient satisfaction, lens stability, and any complications. Researchers measure outcomes such as distance-corrected intermediate visual acuity, binocular defocus curve, contrast sensitivity, and vision-related quality of life to help guide lens selection for future patients.

Age: 22Years - 85YearsAll GendersPhase Not Applicable
1 location
C

Actively Recruiting

Researchers are investigating the best timing for radiotherapy in women with high-risk breast cancer who have received neoadjuvant chemotherapy. The study compares preoperative radiotherapy to the standard postoperative radiotherapy to see if it improves disease-free survival and reduces radiation-related late side effects. This is a randomized phase III trial conducted internationally to address an important gap in breast cancer treatment. Participants are randomly assigned to receive either radiotherapy before surgery or the usual radiotherapy after surgery. Both treatments include radiation to the whole breast or chest wall, with additional boosts to the tumor bed when breast-conserving surgery is performed. If lymph nodes are involved, radiation to regional lymph nodes is also given. Treatments follow national and international guidelines and are carefully monitored. Throughout the study, participants will be followed for 6 to 10 years to assess disease-free survival as the main outcome. Researchers will also track local and regional recurrences, metastasis-free survival, overall and disease-specific survival, cosmetic results, quality of life, arm lymphedema, brachial plexus toxicity, and other treatment-related side effects. Regular evaluations by physicians and patient questionnaires will help monitor safety and effectiveness over the long term.

Age: 18Years +FEMALEPhase 3
16 locations
L

Actively Recruiting

This research aims to evaluate the long-term outcomes, performance, and ongoing safety of the BIOMONITOR III and its possible successors in everyday clinical use. It focuses on patients with conditions such as tachycardia, atrial fibrillation, syncope, bradycardia, or cryptogenic stroke. The study is designed as an observational registry, allowing additional scientific investigations with minimal extra effort for participants and study sites. Participants will receive a BIOTRONIK Implantable Cardiac Monitor ICM and will use the CardioMessenger device to support the BIOTRONIK Home Monitoring system. The registry monitors patients under routine clinical care without introducing experimental treatments or interventions. Data collection includes the insertion procedure and success rate of the device, as well as the time taken to reach a relevant diagnosis starting from device implantation. Throughout the study, participants will be observed during their regular clinical care visits. Researchers will collect information on device performance, safety, and diagnostic timelines. The study will continue until August 30, 2027, tracking patient outcomes over this extended period. Participation involves consenting to the use of home monitoring technology and agreeing to data collection related to the implanted device and clinical events.

Age: 18Years +All Genders
31 locations
P

Actively Recruiting

Researchers are evaluating the impact of implantable cardioverter-defibrillators ICDs on patients who have survived a myocardial infarction heart attack and have a severely reduced left ventricular ejection fraction LVEF of 35% or less. This group is at increased risk of sudden cardiac death caused by dangerous heart rhythms. Past landmark trials showed ICDs improved survival, but advances in medical therapy have changed patient outcomes, prompting the need to reassess the benefits and risks of ICDs alongside current optimal treatments. In this randomized trial, participants receive optimal medical therapy OMT based on European Society of Cardiology guidelines for managing heart failure and chronic coronary syndromes. One group will also receive an ICD device, while the other group will not. The study compares outcomes between these two groups to determine if OMT without ICD is not worse than OMT with ICD in preventing death. The trial includes patients with symptomatic heart failure and reduced LVEF after a myocardial infarction. Participants will be followed over time with regular evaluations to monitor health and outcomes. Researchers will measure the time from randomization to death from any cause as the primary outcome, with additional assessments including cardiovascular death, sudden cardiac death, hospital readmissions, length of hospital stays, and quality of life over a year. The study is event-driven and expects to observe outcomes about 15 months after the last participant is enrolled. Safety and effectiveness of treatments will be carefully monitored throughout.

Age: 18Years +All GendersPhase Not Applicable
86 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness of nemolizumab Nemluvio4 in treating adults with moderate-to-severe Prurigo Nodularis PN. This observational study aims to measure patient and investigator-reported outcomes over approximately 12 months in routine clinical practice. The study focuses on how patients respond to nemolizumab treatment at 6 months, with ongoing assessments up to a year. Participants who have newly started nemolizumab as determined by their physicians will be observed during their usual care visits. No extra visits, procedures, or lab tests beyond routine care are required. A sub-study in Germany and the UK involves daily patient-reported ratings of itch severity and sleep disturbance for two weeks, collected remotely without clinic visits. During the study, participants will undergo routine evaluations by their doctors, including the Investigator Global Assessment of chronic prurigo stage and questionnaires on itch intensity and sleep quality. These assessments occur at 6 months and continue up to 12 months. This approach allows tracking of treatment effects in real-life settings while minimizing additional burden on participants.

Age: 18Years +All Genders
51 locations

1-10 of 14

1